Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $3.46: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 8.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 28%; Below-average business quality; Negative price momentum.
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company selling Amtagvi (lifileucel), the first approved TIL cell therapy for advanced melanoma, and Proleukin (aldesleukin). Revenue from Amtagvi infusions is recognized upon infusion; Proleukin sells through... Read more
Sell if holding. Engine safety override at $3.46: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 8.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 28%; Below-average business quality; Negative price momentum. Chart setup: RSI 54 mid-range, Bollinger mid-band. Score 5.7/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Iovance Biotherapeutics, Inc.
Latest news
- Chardan Capital Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $14 — benzinga May 7, 2026 positive
- Iovance Biotherapeutics Sees FY2026 Sales $350.000M-$370.000M vs $370.477M Est — benzinga May 7, 2026 neutral
- Iovance Biotherapeutics Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $71.430M Miss $78.396M Estimate — benzinga May 7, 2026 negative
- Iovance Biotherapeutics Option Alert: Fri $4 Calls Sweep (3) Near The Bid: 2008 @ $0.401 Vs 3647 OI; Earnings 5/7 After — benzinga Apr 10, 2026 neutral
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 7.7% daily ATR makes tight stops impractical. Position-size conservatively.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $3.46: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 8.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 28%; Below-average business quality; Negative price momentum. Chart setup: RSI 54 mid-range, Bollinger mid-band. Prior stop was $3.22. Score 5.7/10, moderate confidence.
Take-profit target: $7.66 (+121.4% upside). Prior stop was $3.22. Stop-loss: $3.22.
Quality below floor (3.2 < 4.0).
Iovance Biotherapeutics, Inc. trades at a P/E of N/A (forward -10.1). TrendMatrix value score: 8.1/10. Verdict: Sell.
17 analysts cover IOVA with a consensus score of 3.9/5. Average price target: $9.
What does Iovance Biotherapeutics, Inc. do?Iovance Biotherapeutics is a commercial-stage biopharmaceutical company selling Amtagvi (lifileucel), the first...
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company selling Amtagvi (lifileucel), the first approved TIL cell therapy for advanced melanoma, and Proleukin (aldesleukin). Revenue from Amtagvi infusions is recognized upon infusion; Proleukin sells through distributors for use in Amtagvi regimens and other oncology applications.